Opticyte

30 Years of Science Behind VitalO? Great inventions don’t happen overnight. They take years of research, refinement, and breakthroughs—and Opticyte’s VitalO? Monitor is no exception. CEO Lori Arakaki, PhD, has spent 30 years advancing cellular oxygenation technology. She made her first discovery while earning her PhD in Bioengineering, where she developed a way to measure oxygen inside cells—something to our knowledge no other device could do. “We started Opticyte when it became clear that we could?measure cellular oxygenation in real time. As a bioengineer, I was thrilled with the prospect of bringing our work from the lab to be used in hospitals, where it has the potential to save lives,” Arakaki said. That early research has evolved into the VitalO? Monitor, a breakthrough we think will redefine oxygen monitoring in hospitals and help doctors detect conditions like sepsis, trauma, and heart failure earlier. A Once-in-a-Generation Innovation: ? We believe the first and only device to measure cellular oxygenation noninvasively ? FDA Breakthrough Device Designation due to its innovative approach and potential life-saving quality ? A $3B+ market opportunity with strong intellectual property protection Lori’s journey from PhD research to commercialization is proof that Opticyte is built on decades of science—and now, we are preparing to bring it to market soon. Join us in this exciting journey by investing in Opticyte.? https://lnkd.in/gadw8V6d This Reg CF offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

We're building the future of pulse oximetry. It's overdue! For decades, pulse oximeters have been a standard tool in healthcare, relied upon to measure blood oxygen levels in hospitals and clinics worldwide. But there’s a critical flaw—these devices were initially developed mainly using White test subjects, leading to?dangerously inaccurate readings for people with darker skin tones. The consequences are real. Studies show that?Black patients are nearly 3x more likely?to receive falsely normal oxygen readings, delaying life-saving treatment. This problem, known as?hidden hypoxemia, has contributed to?higher mortality rates?in Black and Hispanic patients, particularly during emergencies like COVID-19 and pneumonia. At Opticyte, we’re changing that. Our?VitalO? Monitor uses?optical spectroscopy?to analyze over?800 wavelengths, compared to the two used by traditional pulse oximeters. VitalO2’s machine learning algorithms ensure more accurate oxygen readings for every patient, regardless of skin tone. The future of pulse oximetry isn’t just about improving a flawed system—it’s about?redefining oxygen monitoring altogether. With your support, we can bring this life-saving technology to market and ensure that?every patient receives the care they deserve. Invest in Opticyte today! https://lnkd.in/gadw8V6d This Reg CF offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. #HealthEquity #Sepsis #Medtech

Explore how we're protecting Opticyte’s Patented Breakthrough Technology. True medical breakthroughs don’t happen often. But when they do, protecting them is critical. At Opticyte, we’ve developed a?fundamentally new way?to measure oxygen in?blood and cells—a capability that no traditional pulse oximeter has. Our proprietary approach has led to?patents pending?in the U.S., Europe, Japan, and China, ensuring that this technology remains?exclusive to Opticyte?as we bring it to market. Here’s why this matters: ??An entirely new approach to pulse oximetry?– Instead of just measuring blood oxygenation (SpO?), our VitalO? Monitor also measures cellular oxygenation (Cell O?)—a crucial early warning indicator of sepsis and organ failure. ??Technology we believe no one else has?– Unlike traditional pulse oximeters, which rely on outdated designs from the 1980s, our device uses optical spectroscopy across 800+ wavelengths for dramatically improved accuracy. ??Protected competitive advantage?– While our patents protect the underlying method of measuring oxygenation, we’re also keeping our machine learning algorithms as trade secrets, ensuring that no competitor can replicate our breakthrough technology. We believe no other company can do what Opticyte is doing.?Our VitalO? Monitor represents the future of oxygen monitoring, and you have the opportunity to be part of this game-changing innovation. Invest today and help us bring this life-saving technology to patients worldwide! https://lnkd.in/gadw8V6d This Reg CF offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

AI or Machine Learning? Here’s What We Use at Opticyte: The term?AI?is everywhere—but what does it really mean when it comes to medical technology? Many companies claim to use AI, but often, the real innovation lies in something more specific:?machine learning. At Opticyte, we don’t just throw around buzzwords. Our?VitalO? Monitor?is powered by?advanced machine-learning algorithms?that analyze?optical spectra from over 800 wavelengths.?We believe these algorithms help us achieve something no other device on the market can:?accurate, real-time, and simultaneous measurements of blood oxygenation (SpO?) and cellular oxygenation (Cell O?). Why does this matter? Because?Cell O? levels provide an early warning sign of organ failure—a critical insight that traditional pulse oximeters can’t offer. This technology has the potential as a?game-changer for emergency and critical care, where faster and more accurate diagnostics can mean the difference between life and death. So, should we call it AI or machine learning? The truth is, while AI is a broader term,?machine learning is the specific technology driving our breakthrough innovations. The real question is:?Will you be part of bringing this life-saving technology to market? Invest in Opticyte today! Explore our StartEngine campaign: https://lnkd.in/gadw8V6d This Reg CF offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

We're working to empower doctors to provide better care. Every day, doctors are faced with the critical challenge of making life-saving decisions with limited information, often under immense time pressure.? Opticyte’s VitalO? monitor is poised to transform the way emergency department and critical care physicians and other clinicians diagnose and treat hard-to-detect conditions like sepsis by providing precise, real-time insights into a patient’s systemic oxygen levels. This innovative technology will empower healthcare providers to intervene earlier,?improving outcomes for patients when every second counts. Every year, sepsis claims the lives of more than 350,000 in the U.S. and causes millions of deaths worldwide.?By equipping doctors with the data they need to detect sepsis early, the VitalO? monitor will not only improve patient care but also offer hope and peace of mind to families during their most vulnerable moments.? Listen to Dr. Rosemary Adamson, a pulmonary and critical care attending physician, describe how the VitalO? could revolutionize care in emergency rooms, helping doctors act faster to save lives: #HealthEquity #Sepsis #Healthtech

As the new year dawns, we want to take a moment to thank each of you for being part of our journey. Whether you’ve followed us, supported our work, or shared our mission with others, your encouragement means the world to us. At Opticyte, we believe that innovation can save lives—and that belief is stronger than ever as we reflect on the progress we’ve made this year. From advancing our groundbreaking VitalO? technology to bringing awareness to the urgent need for equitable, life-saving innovation in oxygen monitoring, 2024 has been a year of impact and growth. Sepsis remains a leading cause of death in U.S. hospitals, claiming hundreds of thousands of lives annually. But thanks to your support, we’re closer than ever to changing that story. Our mission to detect sepsis earlier, address health inequities, and empower clinicians with real-time insights wouldn’t be possible without you. As we look ahead to 2025, we’re filled with hope. Hope for the lives that can be saved. Hope for a future where no family loses a loved one to sepsis or other causes of organ failure. And hope that, together, we can make a meaningful difference in healthcare. We invite you to help us continue this vital work by sharing our campaign with your network or contributing to our StartEngine campaign if you haven’t already. Every action brings us closer to achieving our vision of better outcomes for patients everywhere. Here's the link to learn more: https://lnkd.in/gadw8V6d From all of us at Opticyte, we wish you a joyful holiday season and a bright new year filled with health and hope. With gratitude, Lori and the Opticyte Team This Reg CF offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

What if the pulse oximeter measuring your blood oxygen levels told your clinician that everything was fine, but in reality, your oxygen levels were dangerously low? This scary scenario has been the reality for millions of people, especially those with darker skin tones, due to a phenomenon called hidden hypoxemia. What is Hidden Hypoxemia? Hidden hypoxemia occurs when traditional pulse oximeters overestimate blood oxygen levels, misreading dangerously low levels that can lead to severe complications like organ failure or even death. The issue is especially pronounced in people with darker skin tones, where melanin interferes with the light absorption used by pulse oximeters to measure oxygen levels. Black patients are nearly three times more likely to receive falsely normal oxygen readings than White patients. Patients with hidden hypoxemia face a nearly threefold increase in surgical mortality risk compared to those with accurate readings. The Problem Runs Deep-- Traditional pulse oximeters were developed decades ago, and primarily tested on light-skinned individuals. Even today, FDA standards for testing often fail to represent the diversity of the population, perpetuating an ongoing, dangerous bias with this ubiquitous medical device that is placed on virtually every hospital patient. A Solution Designed for Everyone-- Opticyte’s VitalO? Monitor addresses this problem head-on. By combining traditional blood oxygen saturation (SpO?) with innovative cellular oxygen saturation (Cell O?) measurements, VitalO? offers a clearer, more complete and accurate picture of oxygen levels across all skin tones. Join Us in Fighting Hidden Hypoxemia With your support, we can bring this life-saving technology to the world and ensure that every patient receives the care they deserve—regardless of their skin tone.

This article is concerning, with additional concern because there are fewer articles each month covering the critical need for equity in healthcare, particularly regarding pulse oximeter accuracy across different skin tones. Anil Oza from STAT News offers the latest on this undercovered and crucial issue. The discrepancies in pulse oximeter readings for people with darker skin tones have serious and tragically often fatal, implications for patient care and outcomes, especially in critical conditions. Thank you Noha Aboelata, MD, Sara Gerke and Theodore "Jack" Iwashyna for sharing your voices to raise awareness about this healthcare disparity and the urgent need for change. Opticyte is committed to addressing this challenge with our VitalO? device, aiming to provide accurate pulse oximetry measurements for all patients, regardless of skin tone. Equitable healthcare technology is not just a goal, but a necessity. Read more in the STAT article here: https://lnkd.in/gYqSJci7 and see the graph in declining coverage of the issue in the carousel. #HealthcareEquity #MedicalInnovation #PatientSafety #Sepsis?

Thank you to the FBomb Angels for a meaningful investment that supports our mission to transform health equity and sepsis detection through our VitalO? monitor. We are the health equity change we want to see in the world. This new investment builds on the $2.5 million in venture capital and private investments already raised, alongside more than $4 million in non-dilutive funding. It’s a testament to the growing confidence in Opticyte’s vision and potential, driven by our VitalO? monitor that we believe will revolutionize healthcare and save lives. We invite others to join us in creating a healthier future for all.?

This post from Joel Bervell showcases exactly why we're innovating at Opticyte. Health equity shouldn't take two or even three generations to achieve. He has been raising awareness for years about racial bias in today's pulse oximeters. Data on this bias was first published nearly 50 years ago, in 1976. At Opticyte, we're committed to being part of the solution, ensuring everyone receives accurate, life-saving information to deliver the right care for the right individual at the right time. Our goal is to eliminate disparities in healthcare technology and help enable equitable care for all. To learn more about our mission and how we're addressing this critical issue, watch our informative video on our crowdfunding page: https://lnkd.in/gadw8V6d